Last reviewed · How we verify
ELV/COBI/FTC/TAF
This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication through multiple mechanisms: elvitegravir inhibits integrase, cobicistat boosts drug levels, and emtricitabine and tenofovir alafenamide inhibit reverse transcriptase.
This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication through multiple mechanisms: elvitegravir inhibits integrase, cobicistat boosts drug levels, and emtricitabine and tenofovir alafenamide inhibit reverse transcriptase. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | ELV/COBI/FTC/TAF |
|---|---|
| Sponsor | Fundacion SEIMC-GESIDA |
| Drug class | Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
ELV/COBI/FTC/TAF combines an integrase strand transfer inhibitor (elvitegravir), a pharmacokinetic booster (cobicistat), and two nucleoside/nucleotide reverse transcriptase inhibitors (emtricitabine and tenofovir alafenamide). This multi-mechanism approach targets different steps of the HIV replication cycle, reducing viral load and preventing resistance development. The cobicistat component enhances the bioavailability of elvitegravir and tenofovir alafenamide, allowing for lower doses and improved tolerability.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Nausea
- Diarrhea
- Headache
- Elevated creatinine
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ELV/COBI/FTC/TAF CI brief — competitive landscape report
- ELV/COBI/FTC/TAF updates RSS · CI watch RSS
- Fundacion SEIMC-GESIDA portfolio CI